July 9, 2012
A statement by Allan Coukell, director of medical programs at Pew Health Group, about the enactment of the Food and Drug Administration Safety and Innovation Act.
Read More
June 26, 2012
Allan Coukell, deputy director of the Medical Safety Portfolio of the Pew Health Group, talks about drug safety on C-SPAN.
Read More
June 21, 2012
The U.S. House of Representatives Wednesday passed the Food and Drug Administration Safety and Innovation Act (S. 3187), a bill to support the FDA’s drug and device reviews. “We commend the House for passing the bipartisan Food and Drug Administration Safety and Innovation Act," said Allan Coukell, director of medical programs at the Pew Health Group.
Read More
May 30, 2012
The U.S. House of Representatives passed bipartisan legislation to ensure that the U.S. Food and Drug Administration (FDA) has the funds it needs to approve products that improve health and protect consumers from unnecessary risks.
Read More
May 25, 2012
Allan Coukell, Pew Health Group medical director, is quoted in an Associated Press article about Senate passage of FDA user fee legislation that also aims to improve the safety and quality of imported drugs.
Read More
April 23, 2012
An article in The Wall Street Journal on counterfeit drugs quotes Allan Coukell, medical director at Pew Health Group, over concerns about doctors purchasing cheaper foreign drugs.
Read More
March 29, 2012
Allan Coukell, Director of Medical Programs testifies before the Senate Committee on Health, Education, Labor and Pensions on the importance of the user fee agreement legislation to patients and public health.
Read More
March 28, 2012
An editorial in the Minneapolis Star Tribune about counterfeit drugs quotes Allan Coukell, medical director at Pew Health Group, on the need for a strong, uniform national standards and systems to track authentic drugs.
Read More
March 8, 2012
Allan Coukell, Director of Medical Programs, and Sharon Ladin, Director of the Antibiotics and Innovation Project, testify before the House Committee on Energy and Commerce, Subcommittee on Health on stimulating the development of new antibiotics urgently needed to fight serious and life-threatening bacterial infections
Read More
February 16, 2012
A Wall Street Journal article about counterfeit US drugs quotes Allan Coukell, deputy director at the Pew Health Group.
Read More
February 15, 2012
A statement from Allan Coukell, director of medical programs at the Pew Health Group, about a hearing on the reauthorization of the Medical Device User Fee Act (MDUFA).
Read More
January 17, 2012
Allan J. Coukell, director of medical programs at Pew Health Group, is quoted in the New York Times on the Obama administration's decision to require drug companies to disclose the payments they make to doctors.
Read More
January 17, 2012
The Associated Press quotes Allan Coukell, director of medical programs at Pew Health Group, on the benefits stemming from the Food and Drug Administration's proposal to charge drug manufacturers new application fees for reviewing traditional and generic biotech drugs.
Read More
October 11, 2011
Allan Coukell, director of medical programs at Pew Health group, is quoted in a Minneapolis Star Tribune editorial about the consensus around the Physician Payments Sunshine Act and the need to continue with its implementation.
Read More
September 21, 2011
An opinion editorial in The Hill by Patricia Benson and Allan Coukell outlines the need for a contemporary regulatory system for prescription drugs that will match today’s marketplace.
Read More
September 9, 2011
Allan Coukell, director of medical programs at Pew Health Group, is quoted in Star-Ledger (NJ) article about problems associated with drug makers payments to physicians
Read More
August 30, 2011
A letter to the editor by Allan Coukell, director of Medical Programs at Pew Health Group, highlights the complexity of the drug distribution system and opportunities to protect patients.
Read More
August 30, 2011
A Financial Times analysis of payments to doctors by pharmaceutical companies in the United States quotes Allan Coukell, director of Medical Programs at Pew Health Group, on the need for transparency.
Read More
July 12, 2011
Pew study recommends legislative fixes to reduce risks of counterfeit, adulterated and substandard pharmaceuticals.
Read More
February 24, 2011
Allan Coukell, director of medical safety for Pew Health Group, notes the difficulties inherent in inspecting foreign drug manufacuring facilities under current regulations.
Read More
February 24, 2011
The Pew Health Group's Allan Coukell is quoted in a Wall Street Journal article about a Congressional investigation into the contaminated-heparin crisis of 2008.
Read More
February 3, 2011
An article about payments from pharmaceutical companies to doctors in the Sacremento area quotes the Pew Health Group's Alan Coukell.
Read More
November 8, 2010
An article in The Kansas City Star about the lack of FDA oversight of foreign drugs and supplements, features Allan Coukell, director of Medical Safety for Pew Health Group.
Read More
September 1, 2010
A segment from Newshour about he recent salmonella-tainted egg recall features a comment from the Pew Health Group's Allan Coukell.
Read More
August 3, 2010
The Pew Prescription Project announced support for a new bill that would give the U.S. Food and Drug Administration much-needed authorities to better protect pharmaceutical supply chains. The project also found only one in 10 Americans are confident in the quality of drugs made in India and China.
Read More
August 2, 2010
According to a poll by the Pew Charitable Trusts Prescription Project, voters are sure that drugs manufactured in the United States are free from contamination while drugs manufactered in India or China are not.
Read More
May 16, 2010
Congress is starting to apply pressure to drug manufacturers to report payments made to medical professionals, an article in AZCentral.com says.
Read More
April 12, 2010
The New York Times reports on databases that disclose payments from drug makers to doctors who act as consultants or speakers. The article quotes Allan Coukell, director of the Pew Prescription Project.
Read More
March 31, 2010
A USA Today article on Pfizer's disclosure of its payments to doctors and other health professionals quotes Allan Coukell of the Pew Prescription Project.
Read More
March 31, 2010
The New York Times reports that Pfizer has disclosed details of payments to doctors and other medical professionals for consulting and speaking on its behalf. The article quotes Allan Coukell, director of the Pew Prescription Project.
Read More
March 26, 2010
The Wall Street Journal's Health Blog interviewed Allan Coukell, director of the Pew Prescription Project, about new legislation that will mandate disclosure of financial ties between doctors and drug companies.
Read More
March 23, 2010
The Associated Press reports that the head of the National Institute of Mental Health has called for more transparency in psychiatry’s relationships with the drug industry. Allan Coukell, director of the Pew Prescription Project, is quoted.
Read More
March 22, 2010
Allan Coukell, director of the Pew Prescription Project, issued a statement commending Congress for including provisions from the Physician Payments Sunshine Act in health care reform legislation.
Read More
March 10, 2010
Allan Coukell, director of the Pew Prescription Project, issued a statement today, commenting on a drug safety hearing at the House Energy and Commerce subcommittee on Health.
Read More
February 28, 2010
A Buffalo News article on fees that pharmaceutical companies pay to doctors quotes Allan Coukell of the Pew Prescription Project.
Read More
January 23, 2010
The Miami Herald reports that two more drug companies have released details on their payments to doctors. The piece quotes Allan Coukell of the Pew Prescription Project.
Read More
September 25, 2009
A Boston television station interviewed Allan Coukell of the Pew Prescription Project for a piece on payments from drug companies to doctors.
Read More
September 8, 2009
An article from The Plain Dealer about free samples given to physicians by pharmaceutical companies.
Read More
June 16, 2009
Over one-fifth of U.S. medical schools improved their conflict-of-interest rules in the past year, yet dozens of others lag behind according to the 2009 American Medical Student Association (AMSA) PharmFree Scorecard.
Read More
January 22, 2009
The statement of Robert Restuccia, Executive Director for The Prescription Project, regarding the revised Physician Payments Sunshine Act.
Read More
December 30, 2008
The New York Times reports that the pharmaceutical industry has agreed to a voluntary moratorium on branded goodies such as pens, soap dispensers and mugs. The piece quotes Allan Coukell, director of policy for the Prescription Project.
Read More
December 10, 2008
New guidelines fail to protect consumers from drug risks.
Read More
December 4, 2008
The Prescription Project files a citizens petition with the Food and Drug Administration (FDA), asking the FDA to enforce its rules and require pharmaceutical and medical device companies to withdraw illegal YouTube.com video advertisements for medical devices used in heart, hip and neck surgeries.
Read More
March 12, 2008
Academic detailing provides prescribers with unbiased information, encouraging the use of the safest, most effective and – other things being equal – least costly drugs.
Read More